UCB

UCB is a Belgian drugmaker focused on immune-system and brain diseases; its largest product is BIMZELX for psoriasis and hidradenitis suppurativa, and it also sells treatments for myasthenia gravis and epilepsy.

The world UCB works in, not its own labs. Credits in the footer.

Ticker: UCB
Listing: EURONEXT, Belgium
Next date: Q4 2026 to H1 2027
Chief executive: Jean-Christophe Tellier

Desk view · Opinion · Updated Oct 22, 2026

UCB's BIMZELX is carrying the company, and net cash has turned to net debt after two deals

UCB is growing quickly on BIMZELX and has raised its 2026 guidance twice, with profit and margins expanding. It moved from net cash to net debt in a half that included two June acquisitions, and part of the latest upgrade rests on U.S. net pricing and channel mix. Pipeline readouts and the February results are the next tests.

Read the full desk view

aibio.space Investor Rank · Opinion

8/10 Positive view

BIMZELX is driving fast growth, two guidance raises and doubled profit, though net cash turned to net debt and part of the upgrade rests on U.S. pricing.

Technology: 2/2
Odds: 1/2
Balance sheet: 2/2
Risk: 1/2
Momentum: 2/2

Opinion only. The Investor Rank is aibio.space's opinion of the company's business position, drawn from the public sources on this page. It is not a recommendation to buy, sell or hold any security and it is not investment advice. It does not consider the share price, valuation or your circumstances, and it can change at any time. Payments from companies never affect it. How the rank works.

Technology: Proven and broadening. Bimekizumab has won four head-to-head trials in psoriatic disease, and the pipeline now spans T-cell engagers, cell therapy and anti-tau antibodies.
Odds: Mixed by program. Bimekizumab is established, while bepranemab missed its proof-of-concept endpoint and dapirolizumab met its primary endpoint but not its first ranked secondary.
Balance sheet: Newly leveraged, still profitable. Net financial debt was EUR 2,821 million at June 30 against net cash of EUR 7 million at year-end, with first-half profit of EUR 1,111 million.
Main risk: Pricing and concentration. BIMZELX was about 37% of first-half net sales, and U.S. net pricing helped drive the latest guidance upgrade.
Watch next: Pipeline readouts. The first STACCATO alprazolam phase 3 topline is expected between Q4 2026 and H1 2027, and full-year results arrive February 25, 2027.

Dates

Q4 2026 to H1 2027
First topline from the STACCATO alprazolam phase 3 in prolonged seizures; timing depends on event accumulation Source

By end of 2026
Cizutamig expected to enter phase 2 studies in myasthenia gravis and autoimmune rheumatic disease-associated interstitial lung disease Source

Q1 2027
Commercial availability expected for the ZILBRYSQ autoinjector in the U.S. after the FDA approval UCB announced on October 16, 2026 Source

February 25, 2027
Full-year 2026 results and formal 2027 financial guidance Source

H1 2027
First topline from the pediatric hidradenitis suppurativa phase 3 of BIMZELX Source

The money

Net financial debt of EUR 2,821 million at June 30, 2026, against net cash of EUR 7 million at December 31, 2025. The Neurona and Candid acquisitions closed in June; the half-year report does not split the change by cause. First-half operating cash flow was EUR 369 million. Source

First-half 2026 revenue of EUR 4,270 million, up 22% (27% at constant rates); net sales EUR 4,088 million; adjusted EBITDA EUR 1,736 million. BIMZELX net sales were EUR 1,528 million. 2026 guidance raised on October 22 to revenue growth in the low twenties percent at constant rates. Source

Risks on the record

BIMZELX was EUR 1,528 million of EUR 4,088 million first-half net sales (about 37%), and the October 22 upgrade cited favorable net pricing dynamics in the U.S. as well as patient demand. Source
BRIVIACT lost U.S. exclusivity in February 2026 and fell 13% in the first half; CIMZIA has had no U.S. patent protection since February 2024, with Japanese protection expiring in 2026. Source
Under the August 31 agreement with the U.S. government, UCB will take a more balanced pricing approach for future launches across developed nations; the specific terms are confidential. Source

Questions investors ask

What is aibio.space's Investor Rank for UCB?

8 out of 10, our positive view. BIMZELX is driving fast growth, two guidance raises and doubled profit, though net cash turned to net debt and part of the upgrade rests on U.S. pricing. This is opinion only, not a recommendation to buy, sell or hold, and it does not consider the share price or valuation. Source

Who is the CEO of UCB?

Jean-Christophe Tellier is chief executive officer of UCB. He is quoted in that role in the company's August 31, 2026 announcement of its agreement with the U.S. government. Source

How much does BIMZELX sell?

BIMZELX net sales were EUR 1,528 million in the first half of 2026, up 91% from EUR 799 million, with more than 135,000 patients treated. UCB raised its peak sales guidance for the drug to at least EUR 7 billion. Source

What did UCB say about its 2026 guidance on October 22?

UCB now expects 2026 revenue growth in the low twenties percent at constant exchange rates and adjusted EBITDA growth in the low- to mid-forties. The guidance excludes proceeds from a priority review voucher sale. Source

What is in UCB's agreement with the U.S. government?

UCB will take a more balanced pricing approach for future launches across developed nations, participate in the GENEROUS program and continue U.S. manufacturing investment, including a Georgia biologics plant. UCB says it will not face Section 232 tariffs on current products or future pricing mandates; terms are confidential. Source

Which companies did UCB acquire in 2026?

UCB closed the acquisition of Neurona Therapeutics on June 2 (up to $1.15 billion, $650 million upfront) and Candid Therapeutics on June 17 (up to $2.2 billion, $2 billion upfront). They add the epilepsy cell therapy rezanecel and the BCMA T-cell engager cizutamig. Source

Legal and investor matters

Checked against UCB filings and press releases. Allegations are allegations; nothing here is a finding of fault. Reviewed Oct 25, 2026.

Jul 30, 2026Litigation
Court rules for UCB in Nayzilam patent case against Cipla; Cipla appeals
UCB's half-year report dated July 30, 2026 says Cipla filed an ANDA in 2021 challenging the validity of certain Nayzilam patents, and UCB sued Cipla in the United States. Trial took place in October 2023. In May 2026 the judge ruled in UCB's favor, and Cipla appealed. The report does not give the court or a case number.
United States (court not named) · Status: appealed
UCB Half-Year Financial Report 2026
Jul 30, 2026Litigation
Frau Pharma and UCB trade patent claims in Italy over Fintepla
UCB's half-year report dated July 30, 2026 says Frau Pharma sued UCB, as successor to Zogenix, in Italy in 2025 for alleged infringement of Frau's pending European manufacturing patent related to Fintepla. UCB countersued, and the infringement and nullity cross-claims remain active. In a related matter, an Italian court ruled that Frau owns the patent application, which UCB believes is invalid.
Italian court (not named) · Status: pending
UCB Half-Year Financial Report 2026
Jul 30, 2026Litigation
UCB, Amgen and Lilly sue HRSA over 340B clinic certifications
UCB's half-year report dated July 30, 2026 says UCB sued the Health Resources and Services Administration in December 2024 over its certification of eight Sagebrush subdivisions as 340B covered entities, which UCB says allowed price reductions on its product. Amgen and Eli Lilly are co-plaintiffs. The report also says a court ruled in September 2024 that UCB's 340B contract pharmacy policy does not violate the statute.
Status: pending
UCB Half-Year Financial Report 2026

Pipeline

Program	Indication	Stage
Bimekizumab (BIMZELX), pediatric hidradenitis suppurativa	Children aged 9+ and adolescents with moderate to severe HS	Phase 3 enrollment finished early; first topline expected H1 2027 Source
Dapirolizumab pegol (with Biogen)	Systemic lupus erythematosus	PHOENYCS GO phase 3 met primary endpoint (BICLA 50% vs 35%); confirmatory PHOENYCS FLY recruiting Source
STACCATO alprazolam	Prolonged seizures	Phase 3; first topline expected between Q4 2026 and H1 2027 Source
Fenfluramine (FINTEPLA)	CDKL5 deficiency disorder; Rett syndrome	Filed with FDA (March 2026) and EMA (May 2026) in CDD; Rett phase 3 started Source
Cizutamig (BCMA x CD3 T-cell engager, from Candid)	Autoimmune diseases including myasthenia gravis and SARD-ILD	Phase 1; phase 2 starts planned by end of 2026 Source
Rezanecel (cell therapy, from Neurona)	Drug-resistant mesial temporal lobe epilepsy	Phase 1/2; phase 3 planned H1 2027 Source

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open EURONEXT:UCB on TradingView.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

UCB